Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 28.40
+0.10 (0.35%)
Aug 19, 2026, 1:56 PM CST
Prince Pharmaceutical Revenue
In the year 2025, Prince Pharmaceutical had annual revenue of 1.06B TWD with 53.07% growth. Prince Pharmaceutical had revenue of 608.14M in the half year ending December 31, 2025, with 53.06% growth.
Revenue
1.06B
Revenue Growth
+53.07%
P/S Ratio
0.89
Revenue / Employee
5.67M
Employees
216
Market Cap
1.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.06B | 366.18M | 53.07% |
| Dec 31, 2024 | 690.03M | -63.30M | -8.40% |
| Dec 31, 2023 | 753.33M | 40.80M | 5.73% |
| Dec 31, 2022 | 712.53M | 271.45M | 61.54% |
| Dec 31, 2021 | 441.08M | 145.28M | 49.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Excelsior Biopharma | 936.92M |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| General Biologicals | 215.74M |
| Mediera | 195.89M |